Onyx Pharmaceuticals, Inc. (ONXX)
-NasdaqGS 92.91 
1.43(1.52%) 22 May 04:00 SGT|After Hours
:
92.91 0.00 (0.00%) 22 May 04:10 SGT
| Prev Close: | 94.34 |
|---|
| Open: | 94.50 |
|---|
| Bid: | 92.31 x 100 |
|---|
| Ask: | 93.74 x 100 |
|---|
| 1y Target Est: | 109.18 |
|---|
| Beta: | 1.86 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 92.71 - 95.50 |
|---|
| 52wk Range: | 41.26 - 101.57 |
|---|
| Volume: | 1,329,967 |
|---|
| Avg Vol (3m): | 1,261,670 |
|---|
| Market Cap: | 6.76B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Onyx Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AMat Seeking Alpha(Wed, 08:50 SGT)
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggardat TheStreet(Wed, 05:01 SGT)
- InPlay: Onyx Pharma announces data presentations at the 18th Congress of the European Hematology AssociationBriefing.com(Wed, 04:01 SGT)
- Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology AssociationMarketwired(Wed, 04:00 SGT)
- Will ASCO Unlock Big Value in This Cancer Drug Class?at Motley Fool(Sun, 19 May)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Fri, 17 May)
- Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual MeetingMarketwired(Thu, 16 May)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, 15 May)
- ONYX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Wed, 15 May)
- Aveo plunges as FDA recommends against cancer drugAP(Fri, 3 May)
Key Statistics
| Forward P/E (1 yr): | 168.93 |
|---|
| P/S (ttm): | 15.75 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.72 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.45 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.31 |
|---|
Business Summary
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally.
View More